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Introduction: The safety, lung function efficacy, and symptomatic benefits of combined tiotro-
pium and olodaterol in patients with COPD were established in the 1-year TONADO® studies 
(NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the 
long-term safety profile of tiotropium/olodaterol was investigated in patients with renal impair-
ment in a prespecified safety analysis of the TONADO studies.
Methods: These were 2 replicate, randomized, double-blind, parallel-group, 52-week 
Phase III studies that assessed tiotropium/olodaterol compared with tiotropium or olodaterol 
alone (all via Respimat®) in patients with moderate-to-very severe COPD. In this analysis, 
renal impairment was defined as mild (creatinine clearance [CLcr] 60–89 mL/min), moderate 
(CLcr 30–59 mL/min) or severe (CLcr 15–29 mL/min). Adverse events (AEs) were pooled 
from both studies.
Results: Of 3,041 patients included in this analysis, 1,333 (43.8%) had mild, 404 (13.3%) had 
moderate, and 5 (0.2%) had severe renal impairment; these were distributed equally between 
treatment groups. Almost one-quarter of all treated patients (23.4%) had a history of cardiac 
disorder, 45.6% had hypertension, and 13.3% had glucose metabolism disorders, including dia-
betes. AEs with olodaterol, tiotropium, and tiotropium/olodaterol occurred in 75.1%, 70.8%, 
and 72.0% of patients with no renal impairment, 75.7%, 74.0%, and 73.3% with mild renal 
impairment, and 84.3%, 79.5%, and 79.7% with moderate renal impairment, respectively. There 
was no notable effect of renal impairment on the proportion of patients with an AE, and no 
differences were observed between tiotropium/olodaterol versus the monocomponents. There 
was no difference in the incidence of major adverse cardiac events, renal and urinary tract AEs, 
or potential anticholinergic effects with increasing severity of renal impairment.
Conclusion: Over half the patients enrolled in the TONADO studies had renal impairment, 
and there was a high level of pre-existing cardiovascular comorbidity. The safety and toler-
ability of tiotropium/olodaterol is comparable to the monocomponents, irrespective of the level 
of renal impairment.
Keywords: COPD, renal impairment, comorbidities, tiotropium, olodaterol, safety
Plain language summary
Why was the study done? This analysis of patients participating in two large clinical trials 
(TONADO®; NCT01431274 and NCT01431287) was performed to assess the safety of combined 
treatment with 2 bronchodilators (drugs that open the airways) compared with treatment with a 
single bronchodilator in patients with COPD and impaired kidney function.
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What did the researchers do and find? The researchers found that 
impaired kidney function in patients participating in the TONADO 
studies was common, and that these patients often had other medical 
conditions in addition to COPD. No safety concerns were reported 
in patients with renal impairment who received combined treatment 
with the 2 bronchodilators, tiotropium (a long-acting muscarinic 
antagonist) and olodaterol (a long-acting β
2
-agonist).
What do these results mean? These findings suggest that treat-
ment with tiotropium in combination with olodaterol is as safe as 
treatment with either drug alone in patients with COPD who have 
impaired kidney function. This is important because tiotropium is 
predominantly excreted by the kidneys.
Introduction
COPD is a leading cause of morbidity and mortality, with 
an estimated global prevalence of 11.7% (2010 figures), 
equivalent to 384 million cases.1 In 2005, COPD accounted 
for 5% of all deaths globally, and this is projected to increase 
by 30% over the next 10 years.2 Long-acting bronchodila-
tors are the mainstay of COPD treatment, and are recom-
mended by the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines for maintenance therapy of 
patients with moderate-to-very severe disease.3 Tiotropium 
(Spiriva®) is an established once-daily long-acting musca-
rinic antagonist (LAMA) shown to improve lung function, 
patient-reported outcomes such as dyspnea and quality 
of life, and reduce exacerbations in patients with COPD.4 
Olodaterol (Striverdi® Respimat®) is a recently approved and 
marketed novel long-acting β
2
-agonist (LABA) that provides 
24-hour bronchodilation and symptomatic benefits in patients 
with COPD.5,6 In COPD patients who are not adequately 
controlled despite the use of a single bronchodilator, dual 
bronchodilation with tiotropium and olodaterol as a fixed-
dose combination (FDC) was shown to be safe and effica-
cious over 52 weeks versus the monocomponents in the 
2 Phase III TONADO trials.7
While olodaterol is mainly metabolized by the liver, and 
its metabolites excreted in the feces, tiotropium is primarily 
eliminated by the kidneys, and increasing plasma concentra-
tions have been noted in patients with moderate-to-severe 
renal impairment (creatinine clearance [CLcr] 50 mL/min). 
Although no dose reduction for tiotropium or tiotropium/
olodaterol is recommended for patients with renal impairment 
based on pharmacokinetic data, it is recommended that the 
use of tiotropium and tiotropium/olodaterol in patients with 
severe renal impairment be closely monitored.8–10 Obser-
vational studies have raised questions regarding whether 
urinary retention, particularly in elderly male patients with 
COPD and coexisting lower urinary tract symptoms or 
benign prostate hyperplasia,11 may increase with systemic 
availability of inhaled anticholinergics.12,13
Increasing age is a risk factor for COPD,14 and renal 
impairment is a frequent comorbidity in elderly patients. 
Therefore, there is a concern that this group may be at greater 
risk of adverse events (AEs) due to decreased elimination and 
increased systemic availability of tiotropium. Nevertheless, 
extensive post-marketing experience has been collected with 
the use of tiotropium under real-world conditions in patients 
with comorbidities,15,16 and in a recent pooled analysis includ-
ing 24,555 patients, renal impairment did not result in an 
increased incidence of tiotropium-related AEs.17 To date, 
there have been no known safety issues with renal impairment 
in patients treated with olodaterol, and there are no special 
considerations regarding the use of olodaterol in patients with 
renal impairment, although clinical trial data are lacking for 
patients with severe renal impairment.
Thus, the objective of this analysis was to describe the 
patient risk characteristics associated with renal impair-
ment in patients with moderate-to-very severe COPD being 
treated with tiotropium/olodaterol or the monocomponents 
in the TONADO studies, and to investigate whether renal 
impairment is associated with additional safety concerns in 
this patient population.7
Methods
study design
The TONADO studies were replicate 52-week, multina-
tional, Phase III, multicenter, parallel-group, randomized, 
double-blind, active-controlled studies (Study 1237.5: 
NCT01431274; Study 1237.6: NCT01431287) comparing 
tiotropium/olodaterol FDC with the monocomponents, all 
delivered by the Respimat inhaler, in patients with moderate-
to-very severe COPD (GOLD 2–4).7
The main inclusion and exclusion criteria of the 
TONADO studies are described elsewhere;7 briefly, outpa-
tients aged 40 years with a history of moderate-to-very 
severe COPD (GOLD Stage 2–4); post-bronchodilator 
forced expiratory volume in 1 second (FEV
1
) 80% of 
predicted normal; post-bronchodilator FEV
1
/forced vital 
capacity 70%; and current or ex-smokers with a smok-
ing history of 10 pack-years were included. Patients with 
a significant and unstable disease other than COPD were 
excluded from the study.7 Patients with moderate or severe 
renal impairment (CLcr 50 mL/min) were included, but 
were monitored closely by the investigator.7 The studies were 
conducted in accordance with the Declaration of Helsinki, the 
International Conference on Harmonisation’s Harmonised 
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Tripartite Guideline for Good Clinical Practice, and local 
regulations. Approval was granted from institutional review 
boards (Coordinating Investigator’s [Prof. Roland Buhl] 
Independent Ethics Committee: Ethik-Kommission bei der 
Landesärztekammer Rheinland-Pfalz, Deutschhausplatz 
3, 55116 Mainz, Germany) and patients provided written 
informed consent for these studies.
evaluations and outcome measures
For this analysis, renal impairment categories (normal, mild, 
moderate, and severe) were defined per US Food and Drug 
Administration (FDA) guidance by estimated CLcr calculated 
from serum creatinine (Cockroft–Gault formula) at baseline 
(FDA Guidance for Industry, Clinical Pharmacology; 2010; 
Table 1).18
In a prespecified safety analysis, investigator-reported 
treatment-emergent AEs (TEAEs) were pooled from both 
TONADO studies. In TONADO, all AEs and serious AEs 
(SAEs) occurring from consent through 21 days after the 
last dose of the study medication were collected. The dura-
tion, intensity, relatedness to study drug, treatment required, 
outcomes, seriousness, and action taken were recorded by 
the investigator. AEs were classed as mild, moderate, or 
severe using predefined criteria. An SAE was defined as any 
AE that resulted in death, was immediately life-threatening, 
resulted in persistent or significant disability or incapacity, 
required hospitalization, or resulted in a congenital anomaly/
birth defect. All deaths and SAEs were adjudicated by an 
external independent, blinded adjudication committee of 
clinicians.
analysis
AEs were coded as per the Medical Dictionary for Regulatory 
Activities version 16.1 and assigned to system organ classes 
(SOCs). A composite endpoint of major adverse cardiovas-
cular events (MACE) was included, representing fatal AEs 
in cardiac disorder and vascular disorder SOCs, in combina-
tion with fatal and nonfatal myocardial infarction, fatal and 
nonfatal stroke, as well as sudden death, sudden cardiac 
death, and cardiac death.
Data are reported for patients who received tiotropium/
olodaterol 5/5 μg, tiotropium 5 μg, or olodaterol 5 μg, and 
who had baseline CLcr data available.
Results
Patient population
In TONADO, 5,162 patients were treated and 3,100 received 
study drugs at the marketed doses (olodaterol 5 μg: n=1,038; 
tiotropium 5 μg: n=1,033; tiotropium/olodaterol 5/5 μg: 
n=1,029). Of these, 3,041 patients had baseline CLcr data 
available. At baseline, 1,333 (43.8%) patients had mild 
renal impairment (CLcr 60–89 mL/min) and 404 (13.3%) 
had moderate renal impairment (CLcr 30–59 mL/min), and 
were distributed equally between treatment groups. Five 
patients (0.2%) had severe renal impairment at baseline 
(CLcr 15–29 mL/min); of these, 2 received olodaterol and 
3 received tiotropium/olodaterol (Table 2). Because of the 
small number of patients with severe renal impairment in 
the TONADO studies, these are not included in the stratified 
comparative analysis and are described case by case.
Baseline characteristics and demographics
Approximately two-thirds of patients were male (69.6%–
77.6%), with no differences observed between treatment 
groups or renal impairment category (Table 2). Age and 
smoking history (pack-years) tended to increase with severity 
of renal impairment, with no differences observed between 
treatment groups (Table 2). Notably, the proportion of cur-
rent smokers among all analyzed patients decreased with 
increasing severity of renal impairment (42.6%, 36.5%, and 
22.8% of patients with no, mild, and moderate renal impair-
ment, respectively).
Among all treated patients with normal renal function, 
77.1% received pulmonary medication at baseline, compared 
with 79.9% and 83.2% of those with mild and moderate renal 
impairment, respectively. This increase was not related to an 
increase in COPD severity, as determined by GOLD stage, 
at baseline (Table 2), and no clear differences were observed 
between treatment groups. The proportion of patients receiv-
ing tiotropium at baseline increased with renal impairment 
severity (31.5%, 36.6%, and 39.6% in patients with no, mild, 
and moderate renal impairment, respectively), whereas no 
differences were observed among the proportions of patients 
receiving a LABA (47.4%, 44.6%, and 46.0%, respectively) 
or inhaled corticosteroids (47.0%, 47.1%, and 50.7%, 
respectively). There was some increase in the proportion 
Table 1 renal impairment categories
Impairment Estimated CLcr (mL/min)
normal 90
Mild 60–89
Moderate 30–59
severe 15–29
end-stage diseasea 15 (not on dialysis) or requiring dialysis
Note: anot observed in the TOnaDO® studies due to the inclusion criteria.7
Abbreviation: Clcr, creatinine clearance (determined using the Cockcroft–gault 
formula).
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of patients receiving supportive pulmonary medication 
(mucolytics) at baseline with increasing severity of renal 
impairment, irrespective of no increase in COPD severity 
at baseline (Table 2). Similar proportions of patients with 
normal (61.0%), mild (53.6%), and moderate (62.1%) renal 
impairment received cardiovascular medication at baseline. 
Of the 5 patients with severe renal impairment, 4 (80%) were 
receiving cardiovascular medication at baseline.
Considerable comorbidity was observed in the TONADO 
study population; almost one-quarter of treated patients 
included in this analysis (23.4%) had a history of cardiac 
disorder, 45.6% had hypertension, and 13.3% had disorders 
of glucose metabolism, including diagnosed diabetes mel-
litus. Overall, the proportion of patients with comorbidities 
did not tend to increase uniformly with the severity of renal 
impairment (Figure 1).
?
??
??
??
??
?????????????????????? ????????????????????? ????????????????? ???????????????????? ?????????????????????????????
??????????????
???
????
????
?
?????? ???? ????????
Figure 1 Baseline comorbidity by renal impairment category.
Table 2 Demographic and baseline patient characteristics by renal impairment category
Olodaterol 5 μg 
(n=1,018)a
Tiotropium 5 μg 
(n=1,021)
Tiotropium/olodaterol 5/5 μg 
(n=1,002)b
Renal impairmentc Renal impairmentc Renal impairmentc
Normal Mild Moderate Normal Mild Moderate Normal Mild Moderate
Treated patients, n (%) 433 (42.5) 449 (44.1) 134 (13.2) 455 (44.6) 434 (42.5) 132 (12.9) 411 (41.0) 450 (44.9) 138 (13.8)
Male, n (%) 321 (74.1) 322 (71.7) 104 (77.6) 332 (73.0) 315 (72.6) 99 (75.0) 286 (69.6) 326 (72.4) 97 (70.3)
age, years 60.5±7.4 65.3±7.2 72.1±6.7 59.5±7.5 65.7±7.4 72.7±6.7 59.7±7.6 65.2±7.4 71.3±6.1
BMI, kg/m2 29.1±6.2 23.8±3.9 22.3±3.6 28.6±5.5 24.3±4.0 22.5±3.8 29.3±5.2 23.9±4.0 22.1±4.2
smoking history
Pack years 46.3±24.5 45.5±24.0 71.0±53.0 45.2±26.5 46.7±27.2 72.0±54.5 46.0±24.7 46.1±22.9 64±46.4
gOlD stage, n (%)
gOlD 2
gOlD 3
gOlD 4
227 (52.4)
155 (35.8)
51 (11.8)
223 (49.7)
164 (36.5)
62 (13.8)
12 (9.0)
–
53.6 (28.6)
228 (50.1)
176 (38.7)
50 (11.0)
210 (48.4)
164 (37.8)
60 (13.8)
14 (10.6)
–
49.3 (32.9)
202 (49.1)
156 (38.0)
53 (12.9)
218 (48.4)
182 (40.4)
50 (11.1)
12 (8.7)
–
48.6 (26.9)
study exposure, days 327±96.1 326±96.8 322±99.5 333±91.2 330±92.9 336±85.6 344±74.7 337±83.2 341±76.0
Cardiovascular medication, n (%) 275 (63.5) 244 (54.3) 86 (64.2) 263 (57.8) 242 (55.8) 85 (64.4) 254 (61.8) 228 (50.7) 80 (58.0)
Pulmonary medication, n (%) 339 (78.3) 366 (81.5) 114 (85.1) 335 (73.6) 352 (81.1) 103 (78.0) 328 (79.8) 347 (77.1) 119 (86.2)
Notes: aIncludes 2 patients with severe renal impairment. bIncludes 3 patients with severe renal impairment. cTable 1. Defined using Cockcroft–Gault formula. Data are 
mean ± standard deviation unless otherwise stated.
Abbreviations: BMI, body mass index; gOlD, global Initiative for Chronic Obstructive lung Disease.
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exposure to study medication
Exposure to study drug was similar among all patients, 
irrespective of treatment group or the presence of renal 
impairment. Among patients with severe renal impairment, 
median (minimum–maximum) exposure to olodaterol and 
tiotropium/olodaterol was 368 (range 364–372) and 365 
(range 14–367) days, respectively; no patients with severe 
renal impairment were exposed to tiotropium monotherapy 
(Table 2).
aes and saes
Safety outcomes by baseline renal impairment and treatment 
group are summarized in Table 3, Figures 2 and S1. Overall, 
the proportion of patients with an AE or SAE was high, as 
would be expected in a typically sick population of patients 
with COPD.
Among all treated patients, 72.6% with normal renal 
function reported an AE compared with 74.3% with mild 
and 78.7% with moderate renal impairment (Table 3). 
AEs with olodaterol, tiotropium, and tiotropium/olodaterol 
occurred in 75.1%, 70.8%, and 72.0% of patients with no 
renal impairment; 75.7%, 74.0%, and 73.3% with mild renal 
impairment; and 84.3%, 79.5%, and 79.7% with moderate 
renal impairment, respectively (Table 3; Figures 2 and S1). 
TEAEs occurred in 5.6% of patients with normal renal func-
tion, 6.9% of those with mild renal impairment, and 8.9% 
with moderate renal impairment (Table 3).
SAEs occurred in 15.3% of patients with normal renal 
function, compared with 16.4% and 23.0% of patients 
with mild and moderate renal impairment, respectively 
(Table 3). Among patients receiving olodaterol, tiotro-
pium, and tiotropium/olodaterol, SAEs occurred in 18.2%, 
13.6%, and 14.1% of patients with normal renal function; in 
13.8%, 18.7%, and 16.7% with mild renal impairment; and 
in 26.1%, 19.7%, and 23.2% with moderate renal impair-
ment, respectively (Table 3). The proportion of patients 
with a fatal SAE was low in all treatment groups, with a 
similar incidence reported among those receiving tiotro-
pium/olodaterol regardless of the level of renal impairment 
(normal 1.5%; mild 2.0%; moderate 2.2%; Table 3). SAEs 
requiring hospitalization occurred in 14.1%, 14.7%, and 
19.8% of patients with normal, mild, and moderate renal 
impairment, respectively, with no clear differences between 
treatment groups (Table 3).
Discontinuation of study medication
Generally, lower proportions of patients discontinued 
study treatment, either prematurely or due to an AE, with 
tiotropium/olodaterol compared with the monocompo-
nents, with no effect of renal impairment category observed 
(Figure 3).
safety outcomes in patients with severe 
renal impairment
Among the 5 patients with severe renal impairment, AEs 
occurred in 1 of the 2 patients receiving olodaterol and 3 of 
the 3 patients receiving tiotropium/olodaterol; all patients 
recovered and all continued taking study medication. One 
patient receiving tiotropium/olodaterol experienced an AE 
that was considered by the investigator as possibly related 
to treatment (dysgeusia, insomnia, sudoresis, and tremor); 
this was not considered serious, and the patient recovered 
and continued treatment (Table 4).
Clinically relevant aes associated with 
renal impairment, and use of tiotropium/
olodaterol or the monocomponents
Renal impairment did not affect the incidence of any spe-
cific clinically relevant AE, and there was no difference in 
AE incidence among patients in each group treated with 
tiotropium/olodaterol versus tiotropium or olodaterol alone. 
Notably, exposure-adjusted incidence rates of MACE, renal 
and urinary tract AEs, and potential anticholinergic effects 
were not affected by the level of renal impairment or by 
treatment (Figures 4 and S1A–D).
Discussion
In this subgroup analysis of data from the TONADO studies, 
the safety profile of tiotropium/olodaterol compared with the 
monocomponents was similar to the overall results of the 
study, regardless of the severity of renal impairment. When 
analyzed by each renal impairment category, the proportion 
of patients experiencing an AE was comparable to the results 
of the TONADO studies, in which 74.4% of patients experi-
enced 1 AE.7 Importantly, the proportion of patients experi-
encing an AE did not increase proportionally with the severity of 
renal impairment, and no increase in the proportion of patients 
with an AE or SAE was found with tiotropium/olodaterol 
compared with the monocomponents. Discontinuation of 
study medication occurred less frequently with tiotropium/
olodaterol than with the monocomponents, suggesting better 
tolerability of the FDC in this patient population.7 Overall, these 
data support the safety of dual bronchodilation with tiotropium 
and olodaterol in patients with moderate-to-very severe COPD 
and renal impairment, with no additional safety concerns 
found with combination therapy over the monocomponents.
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Figure 3 Discontinuation of study medication by renal impairment category.
Notes: (A) Prematurely discontinued from trial medication. (B) Discontinued due to adverse event.
Abbreviations: Olo, olodaterol; Tio, tiotropium.
The pharmacokinetics of tiotropium have been well-
characterized in preclinical studies using in vitro and in vivo 
models, and confirmed in clinical studies.19,20 Tiotropium 
binds to human M3 receptors with high affinity, and its slow 
dissociation kinetics account for its long duration of action, 
providing 24-hour bronchodilation.19,20 Similarly, binding, 
kinetic, and functional data support the 24-hour duration of 
olodaterol action, confirming the suitability of both agents 
for once-daily dosing.21 The doses of the monocomponents 
used in the FDC (tiotropium 5 μg, olodaterol 5 μg) are 
based on data from dose-finding studies and are consistent 
with the respective optimum dose when each is used as a 
monotherapy.22 In a 4-week, Phase II, dose-ranging study, 
systemic exposure to olodaterol was shown to increase dose-
proportionally within the dose range 5–20 μg in patients with 
moderate-to-severe COPD.23 Olodaterol is excreted renally 
only at low levels, varying from 0.341% to 0.628% of the 
inhaled dose after 1 and 29 days of dosing, respectively.23 
Olodaterol was associated with a dose-response improve-
ment in lung function, which plateaued at 10–20 μg, with no 
evidence of dose-dependent safety signals.23 Dose-ranging 
studies of tiotropium delivered with the Respimat inhaler 
identified doses of 5 and 10 μg as the most effective and 
safe, based on the assessment of efficacy, safety, and phar-
macokinetics.24 Compared with doses of 5 and 10 μg, 20 μg 
tiotropium resulted in a much higher systemic exposure, 
Figure 2 Incidence of adverse events and serious adverse events by renal impairment category.
Notes: (A) Patients with any ae. (B) Patients with saes. (C) Fatal saes.
Abbreviations: ae, adverse event; Olo, olodaterol; sae, serious ae; Tio, tiotropium.
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without any additional benefits in efficacy; 5 and 10 μg 
were therefore investigated in the Phase III trials.24 When 
administered in combination, the pharmacokinetics of tiotro-
pium and olodaterol are similar to those when either drug is 
administered alone, with no dose adjustments required for 
either tiotropium or olodaterol.10 This is in contrast to other 
LABA/LAMA FDCs.22,25 A Phase I study of aclidinium/
formoterol FDC versus the monocomponents in healthy 
subjects revealed no differences in the relative bioavail-
ability of the FDC compared with the monocomponents; 
Table 4 adverse events in individual patients with severe renal impairment at baseline
Treatment group Age Sex Event (LLT)a Relatedb Serious
Olodaterol 5 μg 70 M none reported – –
79 M Cellulitis of leg
Bronchopneumonia, COPD exacerbation
Cellulitis of oral soft tissues
Chest tightness
epigastric pain
n
n
n
n
n
n
n
n
n
n
Tiotropium 5 μg – – none reported – –
Tiotropium/olodaterol 5/5 μg 80 M Chest pain (at screening before randomization– 
no study medication received)
Upper respiratory tract infection
Bronchitis, COPD exacerbation
n
n
n
n
n
n
80 F Urinary infection
Upper respiratory tract infection
headache
n
n
n
n
n
n
76 M Dysgeusia, insomnia, sudoresis, tremor Y n
Notes: aafter start of randomized study medication. breported by the investigator with a reasonable possibility of being drug-related.
Abbreviations: F, female; llT, Medical Dictionary for regulatory activities low level Term; M, male; n, no; Y, yes.
Figure 4 exposure-adjusted incidence rate ratios and 95% CI (forest plots) of clinically relevant adverse event groups associated with renal impairment comparing tiotropium/
olodaterol with the monocomponents.
Note: aTreatment exposure time adjusted.
Abbreviations: MaCe, major adverse cardiovascular event; Olo, olodaterol; Tio, tiotropium.
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safety of tiotropium/olodaterol in patients with COPD and renal impairment
with tiotropium and mild-to-moderate renal impairment, 
defined as CLcr 60 and 30 mL/min, respectively,17,32 
consistent with the findings of the present analysis.
The long-term general and cardiovascular safety of 
tiotropium and olodaterol in patients with COPD has been 
confirmed in several large clinical trials.4,33–36 Anticholin-
ergics such as tiotropium inhibit parasympathetic-induced 
bronchoconstriction by blocking the action of acetylcholine 
through binding to muscarinic receptors in the airways.37 
Although administered via an inhalation device, the use of 
inhaled LAMAs carries a potential risk of systemic anti-
cholinergic side effects, including dry mouth, constipation, 
glaucoma, urinary retention, hallucinations, and cardiac 
effects, at doses higher than the therapeutic doses, or under 
situations of markedly reduced elimination, particularly in 
elderly patients.38 In the TONADO studies, there was a low 
incidence of potential anticholinergic effects overall.7 Simi-
larly, in the present analysis, the use of tiotropium/olodaterol 
was not associated with any increased risk of anticholinergic 
side effects compared with the monocomponents, regardless 
of the level of renal impairment at baseline.
Longitudinal studies have shown that renal function, as 
measured by estimated GFR or CLcr, declines with advanc-
ing age, with a faster rate of decline observed in older indi-
viduals and in those with lower baseline renal function.39–41 
As the prevalence of COPD increases with advancing age, 
it is likely that a high proportion of patients with COPD also 
have reduced renal function.1 Indeed, 1% and 7% of patients 
with COPD enrolled in Phase III studies have been estimated 
to have mild and moderate renal impairment, respectively.27 
Although advancing age has been associated with reduced 
renal clearance of tiotropium, increased systemic exposure to 
the drug was not found.10 Thus, the findings of this analysis 
support the safety of tiotropium/olodaterol in older patients 
with COPD and impaired renal function.
Generally, data from randomized clinical trials regard-
ing the safety of tiotropium and olodaterol in patients with 
renal impairment are lacking, owing to the exclusion criteria 
of the trials. Therefore, a strength of the present analysis is 
that the large size of the TONADO trials (5,000 patients) 
permits subgroup comparisons regarding renal safety;7 
however, the number of patients with severe renal impair-
ment at baseline remained low, likely reflecting the exclu-
sion criteria of the trials. A limitation of this analysis is that 
CLcr was estimated as per usual practice18 at baseline and 
was not repeated during follow-up; therefore, changes in 
renal function over the course of the study period were not 
considered. The Cockcroft–Gault equation was developed 
however, systemic exposure, as determined by C
max
 and 
AUC
0−t, was 26% and 3% higher with the FDC than with 
aclidinium alone, and 18% and 11% higher than formoterol 
alone, respectively.26
Unlike olodaterol, tiotropium is excreted renally, and 
urinary excretion of tiotropium administered via Respimat 
increases in a dose-dependent manner.24 Renal impairment 
has been associated with increased plasma drug concentra-
tions and reduced clearance following inhalation of tiotro-
pium, either as a dry powder (via HandiHaler®) or solution 
(via Respimat).9 In a study assessing the pharmacokinetics 
of single-dose tiotropium administered intravenously to 
patients with varying levels of renal impairment, increasing 
plasma concentrations of tiotropium were associated with 
decreasing renal function, with the highest levels observed 
in individuals with severely impaired renal function.27 This 
was associated with an increased mean terminal disposition 
half-life. Although the dose used in that study resulted in a 
higher systemic exposure compared with the recommended 
dose of tiotropium, no acute AEs occurred in any individual 
with renal impairment.27 Thus, no dose adjustment is recom-
mended for tiotropium/olodaterol in patients with moderate-
to-severe renal impairment, although it is advised that patients 
should be monitored closely for potential anticholinergic 
effects.10 Similarly, no dose adjustments are recommended 
for the combination therapies indacaterol/glycopyrronium, 
umeclidinium/vilanterol, or aclidinium/formoterol in patients 
with renal impairment.25,28 Aclidinium is rapidly hydrolyzed, 
and a Phase I study showed that very low levels (1%) are 
excreted unchanged renally, regardless of the presence of 
varying levels of renal impairment, suggesting that a dose 
adjustment is not needed in this population.29 In patients with 
severe renal impairment, there was no evidence of an increase 
in systemic exposure of either umeclidinium or vilanterol 
when administered in combination, with umeclidinium given 
at twice the recommended dosage.30
A database analysis suggested that tiotropium adminis-
tered via the Respimat device may confer an increased risk 
of mortality among patients with stage 3–5 chronic kidney 
disease, defined as an estimated glomerular filtration rate 
(GFR) 60 mL/min/1.73 m2 body surface area, while no 
increased risk was suggested in patients with normal renal 
function (adjusted hazard ratio [HR] 1.52; 95% CI: 1.02–
2.28 versus HR 0.84; 95% CI: 0.25–2.85, respectively).31 
However, in a pooled analysis of 10,805 patients with renal 
impairment enrolled in 22 placebo-controlled trials of tiotro-
pium (HandiHaler 18 μg and Respimat 5 μg), no association 
was found between the incidence of AEs, SAEs, or fatal SAEs 
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based on the observation that CLcr decreases linearly with 
age, and predicts CLcr based on measured serum creati-
nine, age, and weight. However, these initial observations 
were based on males and assumed that renal function was 
stable, and the calculation was not adjusted for body surface 
area.42 Although recommended by the US FDA for use in 
pharmacokinetics studies, the ability of the Cockcroft–Gault 
equation to correctly estimate GFR has been questioned, and 
it has been shown to be imprecise in reflecting GFR based 
on the measurement of creatinine secretion, particularly in 
patients aged 65 years, who may have a reduced GFR 
despite normal serum creatinine levels.43–45 Nevertheless, the 
results of the present analysis are reassuring, with no safety 
signals observed in patients with COPD and varying levels 
of renal impairment, as determined by means of CLcr.
Conclusion
In this subgroup analysis of patients with renal impairment 
participating in the TONADO studies, there was no increase 
in the proportion of patients with AEs or SAEs with tiotro-
pium/olodaterol versus tiotropium or olodaterol alone, and 
the presence of renal impairment did not affect the incidence 
of AEs in any treatment group. These findings indicate that 
the safety and tolerability of tiotropium/olodaterol FDC 
delivered via Respimat are comparable to the monocompo-
nents regardless of the level of renal impairment, with no 
additional safety signals observed.
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Figure S1 (Continued)
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Figure S1 Exposure-adjusted incidence rate ratios and 95% confidence intervals (forest plots) of clinically relevant adverse event groups associated with renal impairment 
comparing tio/olo with the monocomponents.
Notes: (A) Cardiovascular events. (B) respiratory events. (C) Urinary tract events. (D) Potential anticholinergic events. aTreatment exposure time adjusted.
Abbreviations: MaCe, major adverse cardiovascular event; Olo, olodaterol; Tio, tiotropium.
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